Detail akcie Phylogica online

Business Summary: PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Financial Summary: BRIEF: For the six months ended 31 December 2025, PYC Therapeutics Ltd revenues decreased 13% to A$11M. Net loss decreased 11% to A$22.8M. Revenues reflect R&D tax incentive decrease of 25% to A$8.9M. Lower net loss reflects Research & Development Expense - Balanci decrease of 19% to A$24.1M (expense), Travel and accommodation decrease of 84% to A$20K (expense), Professional Services decrease of 42% to A$131K (expense).